Clene Inc. has announced a significant development in its ongoing research efforts with the entry into a subaward agreement for the third year of a National Institutes of Health (NIH) grant. This agreement, dated March 13, 2026, involves a funding amount of up to $8 million, which will be allocated during the period from September 1, 2025, to August 31, 2026. The grant supports an Expanded Access Program for CNM-Au8, a treatment aimed at addressing amyotrophic lateral sclerosis (ALS). This funding is part of a larger NIH grant awarded to Clene and its collaborators, including New York University (NYU) and Columbia University, which collectively amount to $45.1 million over four years. The NIH grant is pivotal in advancing Clene's research and development initiatives, particularly in the field of neurology, where ALS remains a critical area of focus. The agreement stipulates that funds will be disbursed based on the submission of invoices by Clene to NYU for reimbursement, ensuring a structured financial oversight mechanism. Furthermore, the agreement allows Clene to utilize its background intellectual property developed prior to the subaward, while maintaining control over its proprietary data. This strategic funding is expected to bolster Clene's operational execution and enhance its position in the competitive biopharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.